Stockscreener 앱 받기
2.00
0.00%
0.00
시간 외 거래:
1.95
-0.05
-2.50%
Autonomix Medical Inc 주식(AMIX)의 최신 뉴스
Autonomix Medical reports promising results in first-in-human trial for novel cancer pain therapy - Proactive Investors
Autonomix reports significant pain relief in cancer trial - Investing.com Australia
Autonomix Highlights Compelling Patient Testimonial Showing - GlobeNewswire
Breakthrough Cancer Pain Treatment Eliminates Opioid Use in 100% of Responding Patients, Trial Shows - Stock Titan
Mariner LLC Sells 11,756 Shares of Autonomix Medical, Inc. (NASDAQ:AMIX) - Defense World
It is Poised to be a Bull Market for Autonomix Medical Inc (AMIX) - Sete News
Autonomix Medical, Inc. Announces Successful Initial Trial Phase and Plans for Market Expansion Study in Pancreatic Cancer Pain Management - Nasdaq
Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in Virtual Investor 'What This Means” Segment Highlighting Key Learnings from First-In-Human Trial and Extension into Visceral Cancer Pain - The Manila Times
Autonomix Medical, Inc. (NASDAQ: AMIX) Participates in Virtual Investor “What This Means” Segment Highlighting Key Learnings from First-In-Human Trial and Extension into Visceral Cancer Pain - GlobeNewswire
Autonomix Medical Pain Treatment Trial Success Leads to Cancer Market Expansion | AMIX Stock News - Stock Titan
Autonomix Medical Inc (AMIX) Outlook: Looking Back For Insights - Stocksregister
Maxim Group Initiates Coverage on Autonomix Medical (NASDAQ:AMIX) - Defense World
Maxim Initiates Coverage of Autonomix (AMIX) with Positive Outlo - GuruFocus
Autonomix (AMIX) Reports Promising Trial Results in Pancreatic C - GuruFocus
How is AMIX’s stock performing after recent trades? - uspostnews.com
Autonomix Medical Inc (AMIX) Stock: Exploring a Year of Highs, Lows, and Trading Volume - investchronicle.com
Autonomix provides update on initial phase on delivering transvascular energy - TipRanks
Autonomix advances pain treatment in cancer trials - Investing.com Australia
Autonomix Medical, Inc. Reports Positive Outcomes in Initial Phase of First-in-Human Proof-of-Concept Trial in Pancreatic Cancer Pain and Initiates Market Expansion Study for Visceral Cancer Pain - The Manila Times
Maxim Initiates Coverage of Autonomix (AMIX) with Positive Outlook | AMIX Stock News - GuruFocus
Autonomix advances pain treatment in cancer trials By Investing.com - Investing.com UK
Autonomix Medical, Inc. Reports Positive Outcomes in - GlobeNewswire
Revolutionary Cancer Pain Treatment Shows 100% Success Rate: Autonomix Medical's Breakthrough Trial Results - Stock Titan
Maxim Group Initiates Coverage of Autonomix Medical (AMIX) with Buy Recommendation - Nasdaq
Maxim Group Initiates Coverage on Autonomix Medical With Buy Rating, $5 Price Target - marketscreener.com
Autonomix Medical, Inc. to Present Innovative Neural Ablation Technology at EuroPCR 2025 - Nasdaq
Autonomix Medical, Inc. Technology and Early Proof-of-Concept Study Results to be Featured in Poster Presentation at the World-Leading Course in Interventional Cardiovascular Medicine, EuroPCR - GlobeNewswire
Autonomix Medical announces inducement grant - Medical Buyer
Autonomix Medical, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Autonomix Medical Expands Team with Strategic 5,000-Share Stock Option Grant to New Key Employee - Stock Titan
Autonomix Medical secures new European patent for nerve tech By Investing.com - Investing.com South Africa
Autonomix Medical Granted European Patent For Catheter-Based Neuromodulation Technology - Nasdaq
Autonomix Gains European Patent for Catheter-Based Tech - Medical Product Outsourcing
Autonomix Medical secures new European patent for nerve tech - Investing.com
Autonomix Medical Granted New European Patent For Proprietary Catheter-Based Technology - marketscreener.com
Autonomix Medical, Inc. Granted New European Patent for Proprietary Catheter-Based Technology - GlobeNewswire
Medical Breakthrough: Autonomix's New EU Patent Powers Multi-Condition Treatment Platform - Stock Titan
Autonomix (AMIX) Secures European Patent for Neuromodulation Inn - GuruFocus
Autonomix stock plunges to 52-week low of $1.52 amid steep annual decline - Investing.com Australia
Autonomix stock plunges to 52-week low of $1.52 amid steep annual decline By Investing.com - Investing.com South Africa
Analyzing Globus Medical (NYSE:GMED) & Autonomix Medical (NASDAQ:AMIX) - Defense World
Autonomix to begin U.S. clinical studies for FDA approval By Investing.com - Investing.com South Africa
Autonomix to begin U.S. clinical studies for FDA approval - Investing.com
Autonomix Medical, Inc. Engages Leading Medical Experts to - GlobeNewswire
Top Medical Experts Join Forces to Advance Revolutionary Pancreatic Cancer Pain Treatment - Stock Titan
Autonomix Medical, Inc. to Highlight Technology and Early Proof-of-Concept Study Results in a Poster Presentation at the 2025 European Conference on Interventional Oncology (ECIO) - GlobeNewswire
Revolutionary Pancreatic Cancer Pain Treatment: Autonomix Medical Reveals First Clinical Results at ECIO 2025 - Stock Titan
Autonomix Medical, Inc. (NASDAQ:AMIX) Short Interest Update - Defense World
Patent Granted to Autonomix Medical for Sensing Data Collection - Medical Product Outsourcing
Autonomix stock plunges to 52-week low of $1.81 amid market challenges By Investing.com - Investing.com South Africa
Autonomix stock plunges to 52-week low of $1.81 amid market challenges - Investing.com Australia
Financial Analysis: INVO Bioscience (NASDAQ:INVO) & Autonomix Medical (NASDAQ:AMIX) - Defense World
Autonomix Medical announces inducement grant under Nasdaq listing rule 5635(C)(4) - Marketscreener.com
11.62%
0.20%
자본화:
|
볼륨(24시간):